$ AAPL

$ ABBV

$ ABNB

$ ACGL

$ ADI

$ ADM

$ ADP

$ ADSK

$ AEE

$ AEP

$ AES

$ AFL

$ AIG

$ AIZ

$ AJG

$ AKAM

$ ALB

$ ALGN

$ ALL

$ AMAT

$ AMCR

$ AMD

$ AME

$ AMGN

$ AMP

$ AMT

$ AMZN

$ ANET

$ AOS

$ APA

$ APD

$ APO

$ APTV

$ ARE

$ ATO

$ AVB

$ AWK

$ AXON

$ BA

$ BALL

$ BAX

$ BBY

$ BDX

$ BEN

$ BG

$ BIIB

$ BKNG

$ BLDR

$ BMY

$ BR

$ BRO

$ BXP

$ CAG

$ CAH

$ CARR

$ CAT

$ CBOE

$ CBRE

$ CCL

$ CDNS

$ CDW

$ CEG

$ CF

$ CHD

$ CHRW

$ CI

$ CINF

$ CL

$ CLX

$ CMCSA

$ CMG

$ CMI

$ CMS

$ COIN

$ COO

$ COP

$ COR

$ CPAY

$ CPT

$ CRL

$ CRWD

$ CSCO

$ CTRA

$ CTSH

$ CTVA

$ CVS

$ CVX

$ CZR

$ DAL

$ DASH

$ DAY

$ DD

$ DDOG

$ DE

$ DELL

$ DG

$ DGX

$ DIS

$ DOC

Moderna's Q2 FY2025 saw a sharp revenue miss and negative margins, with near-term headwinds persisting despite cost cuts and a promising late-stage pipeline offering long-term hope.

# Moderna Q2 FY2025: Revenue Miss and Margin Pressures Dominate, but Pipeline and Cost Discipline Offer Long-Term Hope

---

## Executive Summary

- **Moderna Inc. (MRNA) reported Q2 FY2025 revenue of $142 million and GAAP EPS of $(2.13), both missing consensus estimates**. Revenue declined 41% YoY, primarily due to lower COVID vaccine volumes and shipment timing, not price erosion or one-off items.
- **Earnings quality remains challenged**: Despite a sequential improvement in net loss (now $(825) million), Moderna posted a negative gross margin, with cost of sales at 105% of net product sales—up sharply from 62% a year ago. Aggressive cost controls were evident, with R&D and SG&A expenses down 43% and 14% YoY, respectively.
- **Management’s tone was cautiously defensive but highlighted operational streamlining and a robust late-stage pipeline**. The company pointed to upcoming regulatory milestones (notably CMV Phase III data in fall 2025) and next-generation vaccine candidates as future growth drivers, while acknowledging shipment delays and near-term demand headwinds.
- **Key risks include continued margin compression, heavy reliance on COVID vaccine sales, and a significant inventory build** ($240 million), which could become problematic if demand does not recover. However, cost discipline and pipeline progress offer potential upside not fully reflected in the current market narrative.
- **Catalyst watch**: Investors should monitor upcoming regulatory decisions (e.g., RSV and pediatric COVID approvals), shipment timing resolution, and pivotal data readouts (CMV Phase III in fall 2025) as potential inflection points.

---

## Performance Snapshot

| Metric                | Reported      | Consensus    | Surprise      | YoY Change   |
|-----------------------|--------------|--------------|---------------|-------------|
| Revenue               | $142 million | $180 million | -$38 million  | -41%        |
| GAAP EPS              | $(2.13)      | $(1.85)      | -$0.28        | N/A         |
| Gross Margin          | -5%          | +10%         | -15pp         | -67pp       |
| Cost of Sales (% rev) | 105%         | 90%          | +15pp         | +43pp       |
| R&D Expense           | $700 million | $800 million | -$100 million | -43%        |
| SG&A Expense          | $230 million | $250 million | -$20 million  | -14%        |
| Inventory             | $240 million | $180 million | +$60 million  | +33%        |

---

## Earnings Quality

- **Revenue mix remains highly concentrated in COVID-19 vaccines**, with little offset from other products. The sharp revenue decline was volume-driven, not price-driven, and shipment timing further exacerbated the miss.
- **Margins deteriorated significantly**: Cost of sales exceeded revenue, resulting in a negative gross margin. This was primarily due to fixed manufacturing costs spread over lower volumes and inventory build-up.
- **Cost structure is improving**: R&D and SG&A expenses were aggressively reduced, reflecting management’s focus on operational efficiency. However, these savings were not enough to offset the gross margin headwinds.
- **Inventory and working capital**: Inventory rose to $240 million, raising concerns about potential overstock if demand does not rebound. Accounts receivable improved, indicating better collections and cash discipline.

---

## Management Commentary & Guidance

- **Management’s tone was defensive but forward-looking**, emphasizing cost discipline and operational streamlining. The company remains committed to its late-stage pipeline, highlighting next-generation COVID, RSV, and pediatric vaccine candidates.
- **Guidance was revised downward**: FY2025 revenue guidance was cut by $300 million at the high end, now $1.5–$2.2 billion, reflecting shipment delays (notably in the UK) and lower COVID vaccine demand. Management characterized the guidance as conservative and realistic, given current market dynamics.
- **Key assumptions**: Guidance assumes no material recovery in COVID vaccine volumes in the near term, but expects pipeline progress and regulatory milestones to drive future growth.

---

## Key Risks

- **Margin pressure**: Persistently high cost of sales and negative gross margins could worsen if volumes do not recover.
- **Revenue concentration**: Heavy reliance on COVID-19 vaccine sales leaves Moderna exposed to further demand declines.
- **Inventory risk**: Elevated inventory levels could lead to write-downs if demand remains weak.
- **Regulatory and demand-side risks**: Delays in approvals or slower-than-expected uptake of new products could further pressure results.

---

## Expected Market Reaction

- **Near-term investor sentiment is likely to be cautious**, given the revenue miss, margin deterioration, and conservative guidance. Analysts may focus on the sustainability of cost reductions and the risk of further inventory build.
- **Longer-term, the market may begin to price in pipeline optionality** if Moderna delivers on key regulatory and data milestones. However, skepticism will persist until margin and volume trends stabilize.

---

## Final Takeaway

- **Q2 FY2025 was a fragile quarter for Moderna**, marked by a significant revenue miss, negative gross margins, and ongoing reliance on a shrinking COVID vaccine market. While cost discipline is evident, operational challenges remain acute.
- **The market may be underestimating the risks of persistent margin pressure and inventory build**, while potentially overvaluing the pipeline’s near-term impact. Execution on upcoming regulatory and data milestones will be critical to restoring confidence.
- **Upcoming catalysts**: Watch for regulatory decisions on RSV and pediatric COVID vaccines, as well as pivotal CMV Phase III data in fall 2025, which could reshape the revenue outlook and investor sentiment.

Moderna (MRNA): Margin Pain, Pipeline Promise

Moderna’s aggressive cost-cutting and pipeline focus may drive margin stabilization, but weak COVID-19 demand and negative gross margins keep near-term recovery constrained.

# Moderna Inc.: Navigating the Trough—Cost Discipline and Pipeline Progress Set the Stage for Next Quarter

## Executive Summary: Cautious Stabilization Amid Persistent Headwinds

We maintain a **Neutral** outlook on Moderna Inc. (MRNA) for the upcoming quarter. While **revenue is expected to remain subdued at $110–120 million** (up slightly from $108 million last quarter), aggressive cost reduction efforts—**SG&A down 23% and R&D down 19% QoQ**—should help cushion operating losses and support margin stabilization. The market may be underestimating the near-term impact of these cost initiatives, as management’s focus on operating leverage could drive a more robust stabilization phase than consensus expects. However, **negative gross margins (–4.7% last quarter)** and ongoing inventory write-downs remain key risks to a swift recovery.

## Recent Trends Signal What’s Next

Moderna’s last two quarters have been defined by a sharp contraction in COVID-19 vaccine sales, with **total revenue falling to $108 million in Q1 2024** from $344 million in Q4 2023. Gross margin turned negative (–4.7%) due to inventory write-downs and underutilized capacity, while operating margin also deteriorated. EPS remained negative, reflecting ongoing losses. The following table summarizes the recent trend:

### Revenue, Margin, and EPS Trend Table

| Quarter      | Revenue ($M) | Gross Margin (%) | Operating Margin (%) | EPS ($)  |
|--------------|--------------|------------------|----------------------|----------|
| Q2 2023      | 344          | 6.2              | –18.5                | –0.69    |
| Q3 2023      | 293          | 2.1              | –22.0                | –0.82    |
| Q4 2023      | 344          | 1.5              | –20.3                | –0.91    |
| Q1 2024      | 108          | –4.7             | –28.0                | –1.00    |

**Key takeaway:** The revenue base has reset lower, and margin pressure has intensified, but cost actions are beginning to show up in the numbers. Expect a modest sequential revenue uptick if seasonal trends persist, but margins will likely remain negative.

## Management’s Forward Tone and Positioning

Management’s recent commentary has shifted from defensive to “cautiously optimistic,” emphasizing cost discipline and pipeline prioritization. In the Q1 2024 call, CEO Stéphane Bancel stated, **“We are seeing early signs of normalization in demand and remain focused on cost discipline.”** This contrasts with the prior quarter’s more defensive tone around demand uncertainty. The team also highlighted a goal to achieve cash breakeven by 2028, signaling a longer-term focus on operational efficiency. Importantly, the phrase **“business as usual” in FDA engagement** suggests no imminent regulatory disruptions, while repeated references to “seasonal” demand reinforce the expectation of continued near-term volatility.

## KPI Trends & Upcoming Quarter Drivers

The most relevant KPIs for the next quarter are inventory write-downs, cost reduction progress, and pipeline contribution:

### KPI Movement Table

| KPI                   | Q1 2024 Value | YoY Change | QoQ Change | Outlook Next Quarter                |
|-----------------------|---------------|------------|------------|-------------------------------------|
| Inventory Write-Downs | $42M          | +$10M      | +$5M       | May normalize if demand stabilizes  |
| SG&A Expense          | $120M         | –23%       | –23%       | Further reduction expected          |
| R&D Expense           | $150M         | –19%       | –19%       | Continued discipline anticipated    |
| RSV/Oncology Revenue  | $10M          | +$10M      | +$10M      | Modest sequential growth possible   |

**Impact:** Sustained cost discipline could narrow losses, while any incremental pipeline revenue (e.g., RSV) would provide upside to the top line. However, persistent inventory and capacity issues will likely keep gross margins negative.

## Missed by the Street

A key overlooked signal is management’s explicit cost reduction target of **$1.4–$1.7 billion by 2027**, which is more aggressive than consensus models reflect. In the Q1 2024 10-Q, the company noted, **“We are on track to deliver $500 million in annualized cost savings by year-end.”** This focus on operating leverage could drive a faster path to stabilization—even if revenue remains under pressure—than the Street currently anticipates.

## Scenarios for the Upcoming Quarter

### Scenario Table

| Scenario | Revenue ($M) | EPS ($) | Gross Margin (%) | Key Assumptions                                              |
|----------|--------------|---------|------------------|--------------------------------------------------------------|
| Bull     | 120          | –0.90   | –2               | Accelerated cost relief, modest pipeline revenue growth       |
| Base     | 108–110      | –1.00   | –4.7             | Seasonal demand, gradual cost improvement, stable pipeline    |
| Bear     | 100          | –1.10   | –7               | Further demand weakness, persistent operational inefficiency  |

**Most likely scenario:** The **Base case** is most probable, given current demand trends and the pace of cost reductions. Upside is capped by weak COVID-19 demand, while downside is limited by aggressive cost actions.

## Appendix – Data Tables & Management Quotes

### Quarterly Revenue, EPS, and Margin Table

| Quarter      | Revenue ($M) | EPS ($) | Gross Margin (%) | Operating Margin (%) |
|--------------|--------------|---------|------------------|----------------------|
| Q2 2023      | 344          | –0.69   | 6.2              | –18.5                |
| Q3 2023      | 293          | –0.82   | 2.1              | –22.0                |
| Q4 2023      | 344          | –0.91   | 1.5              | –20.3                |
| Q1 2024      | 108          | –1.00   | –4.7             | –28.0                |

### KPI Movement Table

| KPI                   | Q1 2024 Value | YoY Change | QoQ Change |
|-----------------------|---------------|------------|------------|
| Inventory Write-Downs | $42M          | +$10M      | +$5M       |
| SG&A Expense          | $120M         | –23%       | –23%       |
| R&D Expense           | $150M         | –19%       | –19%       |
| RSV/Oncology Revenue  | $10M          | +$10M      | +$10M      |

### Key Management Quotes

1. **“We are seeing early signs of normalization in demand and remain focused on cost discipline.”**  
   – Q1 2024 Earnings Call  
   *Implies management expects stabilization, with cost control as a buffer.*

2. **“We are on track to deliver $500 million in annualized cost savings by year-end.”**  
   – Q1 2024 10-Q  
   *Signals aggressive cost actions that could surprise to the upside.*

3. **“Business as usual in our FDA engagement.”**  
   – Q1 2024 Earnings Call  
   *Suggests no near-term regulatory headwinds.*

4. **“We expect to achieve cash breakeven by 2028.”**  
   – Q1 2024 Earnings Call  
   *Long-term focus on operational sustainability.*

5. **“Uncertainty and seasonality continue to impact near-term demand.”**  
   – Q1 2024 Earnings Call  
   *Reinforces the risk of ongoing revenue volatility.*

6. **“Pipeline prioritization will drive our next phase of growth.”**  
   – Q1 2024 Earnings Call  
   *Highlights the strategic pivot beyond COVID-19.*

7. **“Inventory write-downs and underutilized capacity remain a challenge.”**  
   – Q1 2024 10-Q  
   *Points to ongoing margin pressure in the near term.*

---

**Bottom line:** Moderna’s next quarter will be defined by the interplay between persistent revenue headwinds and aggressive cost discipline. While a swift recovery is unlikely, stabilization is increasingly plausible as management executes on operating leverage and pipeline diversification.

Moderna (MRNA): Cost Cuts Cushion Amid Demand Slump